SUPPLEMENT

Q2 2023 — Financial disclosures

Q2 2023PDF · 9 pages277 KB
Sales 	15,035	$ 	14,593	$ 	3% 	29,522	$ 	30,494	$ 	-3%
Costs, Expenses and Other
Cost of sales 	4,024 	4,216 	-5% 	7,951 	9,596 	-17%
Selling, general and administrative 	2,702 	2,512 	8% 	5,182 	4,834 	7%
Research and development 	13,321 	2,798 	* 	17,597 	5,374 	*
Restructuring costs 	151 	142 	6% 	218 	194 	12%
Other (income) expense, net 	172 	438 	-61% 	259 	1,148 	-77%
(Loss) Income Before Taxes 	(5,335) 	4,487 	* 	(1,685) 	9,348 	*
Income Tax Provision 	637 	538 	1,462 	1,092
Net (Loss) Income 	(5,972) 	3,949 	* 	(3,147) 	8,256 	*
Less: Net Income Attributable to Noncontrolling Interests 	3 	5 	7 	2
Net (Loss) Income Attributable to Merck & Co., Inc. 	(5,975)	$ 	3,944	$ 	* 	(3,154)	$ 	8,254	$ 	*
(Loss) Earnings per Common Share Assuming Dilution (1) 	(2.35)	$ 	1.55	$ 	* 	(1.24)	$ 	3.25	$ 	*
Average Shares Outstanding Assuming Dilution (1) 	2,539 	2,540 	2,539 	2,538
Tax Rate 	-11.9% 	12.0% 	-86.8% 	11.7%
* 100% or greater
(1) Because the company recorded a net loss in the second quarter and first six months of 2023, no potential dilutive common shares were used in the computation of loss per
common share assuming dilution as the effect would have been anti-dilutive.
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
GAAP
% Change
GAAP
% Change
2Q23 	2Q22 June YTD
2023
June YTD
2022

-- 1 of 9 --

Sales 	14,487	$ 	15,035	$ 	29,522	$ 	15,901	$ 	14,593	$ 	30,494	$ 	14,959	$ 	13,830	$ 	59,283	$ 	3% 	-3%
Costs, Expenses and Other
Cost of sales 	3,926 	4,024 	7,951 	5,380 	4,216 	9,596 	3,934 	3,881 	17,411 	-5% 	-17%
Selling, general and administrative 	2,479 	2,702 	5,182 	2,323 	2,512 	4,834 	2,520 	2,687 	10,042 	8% 	7%
Research and development 	4,276 	13,321 	17,597 	2,576 	2,798 	5,374 	4,399 	3,775 	13,548 	* 	*
Restructuring costs 	67 	151 	218 	53 	142 	194 	94 	49 	337 	6% 	12%
Other (income) expense, net 	89 	172 	259 	708 	438 	1,148 	429 	(75) 	1,501 	-61% 	-77%
Income (Loss) Before Taxes 	3,650 	(5,335) 	(1,685) 	4,861 	4,487 	9,348 	3,583 	3,513 	16,444 	* 	*
Income Tax Provision 	825 	637 	1,462 	554 	538 	1,092 	330 	495 	1,918
Net Income (Loss) 	2,825 	(5,972) 	(3,147) 	4,307 	3,949 	8,256 	3,253 	3,018 	14,526 	* 	*
Less: Net Income (Loss) Attributable to Noncontrolling Interests 	4 	3 	7 	(3) 	5 	2 	5 	1 	7
Net Income (Loss) Attributable to Merck & Co., Inc. 	2,821	$ 	(5,975)	$ 	(3,154)	$ 	4,310	$ 	3,944	$ 	8,254	$ 	3,248	$ 	3,017	$ 	14,519	$ 	* 	*
Earnings (Loss) per Common Share Assuming Dilution (1) 	1.11	$ 	(2.35)	$ 	(1.24)	$ 	1.70	$ 	1.55	$ 	3.25	$ 	1.28	$ 	1.18	$ 	5.71	$ 	* 	*
Average Shares Outstanding Assuming Dilution (1) 	2,551 	2,539 	2,539 	2,537 	2,540 	2,538 	2,542 	2,548 	2,542
Tax Rate from Continuing Operations 	22.6% 	-11.9% 	-86.8% 	11.4% 	12.0% 	11.7% 	9.2% 	14.1% 	11.7%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
% Change
2Q 	June
YTD	
June YTD
2023
2Q 	June YTD	1Q 	1Q 	2Q 	3Q 	4Q 	Full Year
2022
Table 1a
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)

-- 2 of 9 --

Second Quarter
Cost of sales 	4,024	$ 	467 	32 	499 	3,525	$
Selling, general and administrative 	2,702 	25 	52 	77 	2,625
Research and development 	13,321 	9 	1 	10 	13,311
Restructuring costs 	151 	151 	151 	-
Other (income) expense, net 	172 	(3) 	194 	191 	(19)
Loss Before Taxes 	(5,335) 	(498) 	(236) 	(194) 	(928) 	(4,407)
Income Tax Provision (Benefit) 	637 	(91) (4) 	(38) (4) 	(44) (4) 	(173) 	810
Net Loss 	(5,972) 	(407) 	(198) 	(150) 	(755) 	(5,217)
Net Loss Attributable to Merck & Co., Inc. 	(5,975) 	(407) 	(198) 	(150) 	(755) 	(5,220)
Loss per Common Share Assuming Dilution (5) 	(2.35)	$ 	(0.16) 	(0.07) 	(0.06) 	(0.29) 	(2.06)	$
Tax Rate 	-11.9% 	-18.4%
June YTD
Cost of sales 	7,951	$ 	1,012 	61 	1,073 	6,878	$
Selling, general and administrative 	5,182 	45 	53 	98 	5,084
Research and development 	17,597 	19 	1 	20 	17,577
Restructuring costs 	218 	218 	218 	-
Other (income) expense, net 	259 	12 	(235) 	573 (3) 	350 	(91)
(Loss) Income Before Taxes 	(1,685) 	(1,088) 	(333) 	235 	(573) 	(1,759) 	74
Income Tax Provision (Benefit) 	1,462 	(196) (4) 	(56) (4) 	51 (4) 	(60) (4) 	(261) 	1,723
Net Loss 	(3,147) 	(892) 	(277) 	184 	(513) 	(1,498) 	(1,649)
Net Loss Attributable to Merck & Co., Inc. 	(3,154) 	(892) 	(277) 	184 	(513) 	(1,498) 	(1,656)
Loss per Common Share Assuming Dilution (5) 	(1.24)	$ 	(0.35) 	(0.11) 	0.07 	(0.20) 	(0.59) 	(0.65)	$
Tax Rate 	-86.8% 	2,328.4%
Only the line items that are affected by non-GAAP adjustments are shown.
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that
providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and
forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. The non-GAAP
information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to
acquisitions and divestitures. Amounts included in research and development expenses primarily reflect expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, for the six-month period
primarily reflect a $37 million loss on the sale of a business and an increase in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the Sanofi-Pasteur MSD joint venture, partially
offset by royalty income.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(5) Because the company recorded a net loss in the second quarter and first six months of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have
been anti-dilutive.
(3) Reflects a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation.
(4) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
Adjustment Subtotal 	Non-GAAP
MERCK & CO., INC.
THREE AND SIX MONTHS ENDED JUNE 30, 2023 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
GAAP 	Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Table 2a
Certain Other Items

-- 3 of 9 --

Second Quarter
Cost of sales 	4,216	$ 	451 	67 	518 	3,698	$
Selling, general and administrative 	2,512 	65 	27 	92 	2,420
Research and development 	2,798 	12 	22 	34 	2,764
Restructuring costs 	142 	142 	142 	-
Other (income) expense, net 	438 	2 	234 	236 	202
Income Before Taxes 	4,487 	(530) 	(258) 	(234) 	(1,022) 	5,509
Income Tax Provision (Benefit) 	538 	(131) (3) 	(40) (3) 	(52) (3) 	(223) 	761
Net Income 	3,949 	(399) 	(218) 	(182) 	(799) 	4,748
Net Income Attributable to Merck & Co., Inc. 	3,944 	(399) 	(218) 	(182) 	(799) 	4,743
Earnings per Common Share Assuming Dilution 	1.55	$ 	(0.16) 	(0.09) 	(0.07) 	(0.32) 	1.87	$
Tax Rate 	12.0% 	13.8%
June YTD
Cost of sales 	9,596	$ 	1,131 	113 	1,244 	8,352	$
Selling, general and administrative 	4,834 	115 	48 	163 	4,671
Research and development 	5,374 	34 	29 	63 	5,311
Restructuring costs 	194 	- 	194 	194 	-
Other (income) expense, net 	1,148 	(112) 	918 	806 	342
Income Before Taxes 	9,348 	(1,168) 	(384) 	(918) 	(2,470) 	11,818
Income Tax Provision (Benefit) 	1,092 	(286) (3) 	(62) (3) 	(204) (3) 	(552) 	1,644
Net Income 	8,256 	(882) 	(322) 	(714) 	(1,918) 	10,174
Net Income Attributable to Merck & Co., Inc. 	8,254 	(882) 	(322) 	(714) 	(1,918) 	10,172
Earnings per Common Share Assuming Dilution 	3.25	$ 	(0.35) 	(0.13) 	(0.28) 	(0.76) 	4.01	$
Tax Rate 	11.7% 	13.9%
Only the line items that are affected by non-GAAP adjustments are shown.
MERCK & CO., INC.
THREE AND SIX MONTHS ENDED JUNE 30, 2022 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b
Non-GAAP
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends.
Management believes that providing non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management
uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is
derived in part using a non-GAAP pretax income metric. The non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with
GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain
other costs related to acquisitions and divestitures. Amounts included in research and development expenses primarily reflect expenses for the amortization of intangible assets. Amounts included in other
(income) expense, net, for the six-month period primarily reflect royalty income and a decrease in the estimated fair value measurement of liabilities for contingent consideration related to the prior termination of the
Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
GAAP 	Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Adjustment Subtotal

-- 4 of 9 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
2023 	2022 	2Q 	June YTD
1Q 	2Q 	June YTD 	1Q 	2Q 	June YTD 	3Q 	4Q 	Full Year 	Nom % 	Ex-Exch % 	Nom % 	Ex-Exch %
TOTAL SALES (1) 	$14,487 	$15,035 	$29,522 	$15,901 	$14,593 	$30,494 	$14,959 	$13,830 	$59,283 	3 	7 	-3 	-
PHARMACEUTICAL 	12,721 	13,457 	26,179 	14,107 	12,756 	26,863 	12,963 	12,180 	52,005 	6 	8 	-3 	-
Oncology
Keytruda 	5,795 	6,271 	12,065 	4,809 	5,252 	10,061 	5,426 	5,450 	20,937 	19 	21 	20 	23
Alliance Revenue – Lynparza (2) 	275 	310 	585 	266 	275 	541 	284 	292 	1,116 	13 	15 	8 	12
Alliance Revenue – Lenvima (2) 	232 	242 	474 	227 	231 	459 	202 	216 	876 	5 	6 	3 	5
Welireg 	42 	50 	92 	18 	27 	45 	38 	40 	123 	89 	89 	105 	105
Alliance Revenue – Reblozyl (3) 	43 	47 	90 	52 	33 	86 	39 	41 	166 	41 	41 	4 	4
Vaccines (4)
Gardasil / Gardasil 9 	1,972 	2,458 	4,430 	1,460 	1,674 	3,133 	2,294 	1,470 	6,897 	47 	53 	41 	48
ProQuad / M-M-R II / Varivax 	528 	582 	1,109 	470 	578 	1,047 	668 	526 	2,241 	1 	1 	6 	7
RotaTeq 	297 	131 	428 	216 	173 	389 	256 	139 	783 	-25 	-24 	10 	13
Vaxneuvance 	106 	168 	274 	5 	12 	16 	16 	138 	170 	* 	* 	* 	*
Pneumovax 23 	96 	92 	188 	173 	153 	325 	131 	145 	602 	-40 	-38 	-42 	-39
Vaqta 	40 	42 	82 	36 	35 	71 	64 	39 	173 	20 	20 	16 	17
Hospital Acute Care
Bridion 	487 	502 	989 	395 	426 	821 	423 	441 	1,685 	18 	19 	21 	23
Prevymis 	129 	143 	273 	94 	103 	197 	114 	118 	428 	39 	42 	39 	43
Dificid 	65 	76 	141 	52 	66 	119 	77 	67 	263 	14 	14 	19 	19
Primaxin 	80 	53 	133 	58 	64 	122 	63 	54 	239 	-16 	-12 	9 	17
Noxafil 	60 	55 	116 	57 	60 	118 	62 	58 	238 	-8 	-3 	-2 	5
Zerbaxa 	50 	54 	104 	30 	46 	76 	43 	49 	169 	17 	18 	36 	39
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 	99 	68 	167 	72 	98 	170 	88 	82 	341 	-31 	-31 	-2 	-2
Adempas (6) 	59 	65 	125 	61 	63 	124 	57 	57 	238 	3 	5 	- 	5
Virology
Lagevrio 	392 	203 	595 	3,247 	1,177 	4,424 	436 	825 	5,684 	-83 	-82 	-87 	-85
Isentress / Isentress HD 	123 	136 	259 	158 	147 	305 	161 	167 	633 	-7 	-4 	-15 	-12
Neuroscience
Belsomra 	56 	63 	119 	69 	69 	137 	62 	59 	258 	-9 	-4 	-14 	-7
Immunology
Simponi 	180 	180 	359 	186 	181 	366 	173 	166 	706 	-1 	-1 	-2 	1
Remicade 	51 	48 	99 	61 	53 	114 	49 	44 	207 	-11 	-10 	-13 	-10
Diabetes (7)
Januvia 	551 	511 	1,062 	779 	756 	1,535 	717 	561 	2,813 	-33 	-30 	-31 	-28
Janumet 	329 	354 	683 	454 	476 	931 	417 	353 	1,700 	-26 	-23 	-27 	-24
Other Pharmaceutical (8) 	584 	553 	1,138 	602 	528 	1,131 	603 	583 	2,319 	5 	8 	1 	4
ANIMAL HEALTH 	1,491 	1,456 	2,947 	1,482 	1,467 	2,949 	1,371 	1,230 	5,550 	-1 	2 	- 	4
Livestock 	849 	807 	1,656 	832 	826 	1,658 	829 	814 	3,300 	-2 	2 	- 	5
Companion Animal 	642 	649 	1,291 	650 	641 	1,291 	542 	416 	2,250 	1 	2 	- 	2
Other Revenues (9) 	275 	122 	396 	312 	370 	682 	625 	420 	1,728 	-67 	-19 	-42 	-20
*200% or greater
(7) Total Diabetes sales were $950 million and $951 million in the first and second quarter of 2023, respectively, and $1,305 million and $1,300 million in the first and second quarter of
2022, respectively.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities.
Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $51 million and $3 million in the first and second quarter of 2023, respectively,
and $114 million and $32 million in the first and second quarter of 2022, respectively.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties and a milestone payment of $20 million received in the first quarter of 2022.
(4) Total Vaccines sales were $3,133 million and $3,557 million in the first and second quarter of 2023, respectively, and $2,481 million and $2,709 million in the first and second quarter of
2022, respectively.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(6) Net product sales in Merck's marketing territories.

-- 5 of 9 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
SECOND QUARTER 2023
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
Global 	U.S. 	International
2Q 2023 	2Q 2022 	% Change 	2Q 2023 	2Q 2022 	% Change 	2Q 2023 	2Q 2022 	% Change
TOTAL SALES (1) 	$15,035 	$14,593 	3 	$7,018 	$6,238 	12 	$8,018 	$8,355 	-4
PHARMACEUTICAL 	13,457 	12,756 	6 	6,570 	5,726 	15 	6,887 	7,030 	-2
Oncology
Keytruda 	6,271 	5,252 	19 	3,863 	3,197 	21 	2,408 	2,055 	17
Alliance Revenue – Lynparza (2) 	310 	275 	13 	144 	143 	1 	166 	132 	26
Alliance Revenue – Lenvima (2) 	242 	231 	5 	163 	128 	28 	79 	103 	-24
Welireg 	50 	27 	89 	49 	27 	84 	2 	*
Alliance Revenue – Reblozyl 	47 	33 	41 	36 	28 	26 	11 	5 	123
Vaccines (3)
Gardasil / Gardasil 9 	2,458 	1,674 	47 	464 	428 	8 	1,994 	1,245 	60
ProQuad / M-M-R II / Varivax 	582 	578 	1 	447 	434 	3 	135 	143 	-6
Vaxneuvance 	168 	12 	* 	147 	11 	* 	20 	*
RotaTeq 	131 	173 	-25 	93 	98 	-5 	37 	75 	-50
Pneumovax 23 	92 	153 	-40 	23 	94 	-76 	69 	59 	17
Vaqta 	42 	35 	20 	29 	16 	76 	13 	19 	-29
Hospital Acute Care
Bridion 	502 	426 	18 	299 	237 	27 	203 	190 	7
Prevymis 	143 	103 	39 	61 	47 	31 	82 	56 	46
Dificid 	76 	66 	14 	68 	63 	8 	8 	3 	144
Noxafil 	55 	60 	-8 	11 	16 	-32 	45 	45 	-
Zerbaxa 	54 	46 	17 	30 	22 	36 	24 	24 	-1
Primaxin 	53 	64 	-16 	-2 	* 	56 	64 	-13
Cardiovascular
Alliance Revenue - Adempas/Verquvo (4) 	68 	98 	-31 	70 	88 	-21 	-2 	10 	-119
Adempas (5) 	65 	63 	3 	65 	63 	3
Virology
Lagevrio 	203 	1,177 	-83 	2 	* 	201 	1,177 	-83
Isentress / Isentress HD 	136 	147 	-7 	56 	67 	-16 	80 	80 	1
Neuroscience
Belsomra 	63 	69 	-9 	21 	19 	10 	42 	50 	-16
Immunology
Simponi 	180 	181 	-1 	180 	181 	-1
Remicade 	48 	53 	-11 	48 	53 	-11
Diabetes (6)
Januvia 	511 	756 	-33 	243 	301 	-19 	267 	455 	-41
Janumet 	354 	476 	-26 	82 	105 	-22 	272 	371 	-27
Other Pharmaceutical (7) 	553 	528 	5 	171 	157 	9 	382 	372 	3
ANIMAL HEALTH 	1,456 	1,467 	-1 	475 	477 	-1 	982 	990 	-1
Livestock 	807 	826 	-2 	165 	164 	1 	643 	662 	-3
Companion Animal 	649 	641 	1 	310 	313 	-1 	339 	328 	4
Other Revenues (8) 	122 	370 	-67 	-27 	35 	-177 	149 	335 	-56
*200% or greater
(6) Total Diabetes sales were $951 million in the second quarter of 2023 and $1,300 million in the second quarter of 2022.
(7) Includes Pharmaceutical products not individually shown above.
(8) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were
$3 million in the second quarter of 2023 and $32 million in the second quarter of 2022.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Total Vaccines sales were $3,557 million in the second quarter of 2023 and $2,709 million in the second quarter of 2022.
(4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales
and commercialization costs.
(5) Net product sales in Merck's marketing territories.

-- 6 of 9 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
JUNE YEAR-TO-DATE 2023
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
Global 	U.S. 	International
June YTD
2023
June YTD
2022 	% Change
June YTD
2023
June YTD
2022 	% Change
June YTD
2023
June YTD
2022 	% Change
TOTAL SALES (1) 	$29,522 	$30,494 	-3 	$13,676 	$13,577 	1 	$15,846 	$16,917 	-6
PHARMACEUTICAL 	26,179 	26,863 	-3 	12,688 	12,498 	2 	13,491 	14,364 	-6
Oncology
Keytruda 	12,065 	10,061 	20 	7,348 	5,976 	23 	4,718 	4,085 	15
Alliance Revenue – Lynparza (2) 	585 	541 	8 	286 	283 	1 	299 	257 	16
Alliance Revenue – Lenvima (2) 	474 	459 	3 	316 	284 	11 	158 	175 	-10
Welireg 	92 	45 	105 	90 	45 	99 	3 	*
Alliance Revenue – Reblozyl (3) 	90 	86 	4 	66 	55 	19 	24 	30 	-22
Vaccines (4)
Gardasil / Gardasil 9 	4,430 	3,133 	41 	880 	846 	4 	3,550 	2,287 	55
ProQuad / M-M-R II / Varivax 	1,109 	1,047 	6 	868 	805 	8 	242 	243 	-
RotaTeq 	428 	389 	10 	273 	273 	- 	155 	116 	34
Vaxneuvance 	274 	16 	* 	241 	16 	* 	33 	1 	*
Pneumovax 23 	188 	325 	-42 	63 	212 	-70 	125 	114 	10
Vaqta 	82 	71 	16 	59 	45 	30 	23 	25 	-8
Hospital Acute Care
Bridion 	989 	821 	21 	576 	432 	33 	413 	389 	6
Prevymis 	273 	197 	39 	116 	87 	34 	157 	110 	43
Dificid 	141 	119 	19 	130 	113 	15 	11 	6 	80
Primaxin 	133 	122 	9 	2 	1 	128 	132 	122 	8
Noxafil 	116 	118 	-2 	25 	25 	-2 	91 	92 	-2
Zerbaxa 	104 	76 	36 	57 	40 	42 	47 	36 	29
Cardiovascular
Alliance Revenue - Adempas/Verquvo (5) 	167 	170 	-2 	153 	159 	-4 	14 	11 	24
Adempas (6) 	125 	124 	- 	125 	124 	-
Virology
Lagevrio 	595 	4,424 	-87 	1,523 	-100 	595 	2,901 	-79
Isentress / Isentress HD 	259 	305 	-15 	108 	128 	-16 	151 	177 	-15
Neuroscience
Belsomra 	119 	137 	-14 	37 	39 	-6 	82 	98 	-17
Immunology
Simponi 	359 	366 	-2 	359 	366 	-2
Remicade 	99 	114 	-13 	99 	114 	-13
Diabetes (7)
Januvia 	1,062 	1,535 	-31 	514 	626 	-18 	548 	909 	-40
Janumet 	683 	931 	-27 	138 	168 	-18 	544 	762 	-29
Other Pharmaceutical (8) 	1,138 	1,131 	1 	342 	317 	8 	793 	814 	-3
ANIMAL HEALTH 	2,947 	2,949 	- 	956 	951 	1 	1,991 	1,998 	-
Livestock 	1,656 	1,658 	- 	338 	335 	1 	1,318 	1,322 	-
Companion Animal 	1,291 	1,291 	- 	618 	616 	- 	673 	676 	-
Other Revenues (9) 	396 	682 	-42 	32 	128 	-75 	364 	555 	-34
*200% or greater
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $1,901 million and $2,605 million on a global share basis for June YTD 2023 and 2022, respectively.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were
$54 million and $146 million on a global share basis for June YTD 2023 and 2022, respectively.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties and a milestone payment of $20 million received in the first quarter of 2022.
(4) Total Vaccines sales were $6,690 million and $5,191 million on a global share basis for June YTD 2023 and 2022, respectively.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales
and commercialization costs.

-- 7 of 9 --

MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3c
2023 	2022 	% Change
1Q 	2Q 	June YTD 	1Q 	2Q 	June YTD 	3Q 	4Q 	Full Year 	2Q 	June YTD
TOTAL PHARMACEUTICAL 	$12,721 	$13,457 	$26,179 	$14,107 	$12,756 	$26,863 	$12,963 	$12,180 	$52,005 	6 	-3
United States 	6,117 	6,570 	12,688 	6,773 	5,726 	12,499 	6,620 	5,871 	24,989 	15 	2
% Pharmaceutical Sales 	48.1% 	48.8% 	48.5% 	48.0% 	44.9% 	46.5% 	51.1% 	48.2% 	48.1%
Europe (1) 	2,326 	2,401 	4,727 	3,309 	2,677 	5,986 	2,427 	2,494 	10,906 	-10 	-21
% Pharmaceutical Sales 	18.3% 	17.8% 	18.1% 	23.5% 	21.0% 	22.3% 	18.7% 	20.5% 	21.0%
China 	1,694 	1,887 	3,581 	1,113 	1,355 	2,468 	1,419 	1,216 	5,102 	39 	45
% Pharmaceutical Sales 	13.3% 	14.0% 	13.7% 	7.9% 	10.6% 	9.2% 	10.9% 	10.0% 	9.8%
Asia Pacific (other than China and Japan) 	703 	705 	1,409 	786 	854 	1,640 	702 	691 	3,034 	-17 	-14
% Pharmaceutical Sales 	5.5% 	5.2% 	5.4% 	5.6% 	6.7% 	6.1% 	5.4% 	5.7% 	5.8%
Japan 	737 	652 	1,390 	965 	1,092 	2,057 	653 	832 	3,542 	-40 	-32
% Pharmaceutical Sales 	5.8% 	4.8% 	5.3% 	6.8% 	8.6% 	7.7% 	5.0% 	6.8% 	6.8%
Latin America 	470 	566 	1,036 	435 	453 	888 	511 	472 	1,871 	25 	17
% Pharmaceutical Sales 	3.7% 	4.2% 	4.0% 	3.1% 	3.6% 	3.3% 	3.9% 	3.9% 	3.6%
Eastern Europe/Middle East/Africa 	381 	370 	751 	450 	339 	789 	360 	320 	1,469 	9 	-5
% Pharmaceutical Sales 	3.0% 	2.7% 	2.9% 	3.2% 	2.7% 	2.9% 	2.8% 	2.6% 	2.8%
Canada 	141 	127 	268 	189 	166 	354 	166 	158 	678 	-23 	-24
% Pharmaceutical Sales 	1.1% 	0.9% 	1.0% 	1.3% 	1.3% 	1.3% 	1.3% 	1.3% 	1.3%
Other 	152 	179 	329 	87 	94 	182 	105 	126 	414 	90 	81
% Pharmaceutical Sales 	1.2% 	1.6% 	1.1% 	0.6% 	0.6% 	0.7% 	0.9% 	1.0% 	0.8%
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.

-- 8 of 9 --

OTHER (INCOME) EXPENSE, NET
2Q23 	2Q22
June YTD
2023
June YTD
2022
Interest income 	(109)	$ 	(15)	$ 	(221)	$ 	(22)	$
Interest expense 	277 	240 	519 	483
Exchange losses 	62 	86 	122 	124
Loss (income) from investments in equity securities, net (1) 	175 	284 	(274) 	991
Net periodic defined benefit plan (credit) cost other than service cost 	(111) 	(27) 	(226) 	(148)
Other, net 	(122) 	(130) 	339 	(280)
Total 	172	$ 	438	$ 	259	$ 	1,148	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests
in investment funds are accounted for on a one quarter lag.
MERCK & CO., INC.
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4

-- 9 of 9 --